Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 06, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital transactions.
- Shares Purchased: 1,570,000 ordinary shares of 25 pence each.
- Purchase Price: 1,132.19 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 9.01% of total voting rights).
- Shares in Issue: 5,373,808,086 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 1,570,000 repurchased shares. Consequently, the number of shares held in Treasury has been updated to reflect this transaction.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,373,808,086) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (484,194,158) and its impact on the 9.01% voting rights representation.
- Note that the repurchase price of 1,132.19 pence per share reflects the market value on May 06, 2008.